Market Overview

UPDATE: Aegis Capital Downgrades Galectin Therapeutics

Related GALT
Watch These 5 Huge Put Purchases In Wednesday Trade
Benzinga's Option Alert Recap From April 18

In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold.

The downgrade comes amid result concerns as to whether or not the company will be able to demonstrate clinical effectiveness of its lead drug candidate GR-MD-02. The concerns arose when the second cohort of its Phase 1b trial did not show the same indications of potential anti-fibrotic efficacy as the previous cohort.

Amid the Aegis downgrade, shares of have dropped more than seven percent.

Latest Ratings for GALT

Mar 2017H.C. WainwrightUpgradesNeutralBuy
Oct 2016FBR CapitalDowngradesOutperformMarket Perform
Sep 2016H.C. WainwrightDowngradesBuyNeutral

View More Analyst Ratings for GALT
View the Latest Analyst Ratings

Posted-In: Aegis Capital Raghuram SelvarajuAnalyst Color Downgrades Price Target Analyst Ratings Movers


Related Articles (GALT)

View Comments and Join the Discussion!